Steven W Pipe

1 month ago | pharmacytimes.com | Luke Halpern |Steven W Pipe

CommentaryVideoMarch 3, 2025Author(s):,Pharmacists are integral to setting patient expectations, monitoring liver health, and ensuring adherence to long-term follow-up for optimal outcomes with etranacogene dezaparvovec. In an interview with Pharmacy Times®, Steven Pipe, MD, a Laurence A.

Dec 11, 2024 | cgtlive.com | Steven W Pipe |Victoria Johnson

This interview originally appeared on our sister site, HCPLive®. "Fitusiran is a highly effective prophylactic agent. The modulation of thrombin generation allows us to achieve effective bleed control with substantially lower doses of factor and bypassing agents, as well as fewer infusions.

Dec 9, 2024 | hcplive.com | Victoria Johnson |Steven W Pipe

Fitusiran prophylaxis, in combination with appropriate bleed management guidelines, allowed fewer infusions and lower doses of clotting factor concentrates (CFC) or bypassing agents (BPAs) to treat breakthrough bleeding in people with hemophilia A or B. These findings, from the ATLAS OLE study, were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, by Steven W. Pipe, MD, Professor and Laurence A.

Jun 5, 2024 | cgtlive.com | Steven W Pipe

“We had concerns about patients who had history of hepatitis.

Dec 12, 2023 | cgtlive.com | Steven W Pipe

“People continue to be interested in the durability of the response, what the patient experience is, as far as bleeding events, the need for Factor IX, additional dosing, and just the overall safety profile... Now through 3 years, 51 of the 54 participants remain off continuous factor IX prophylaxis, so pretty remarkable.